CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 351 enrolled
Drug / intervention
Bexagliflozin tablets, 20 mg +2 moredrug
Likely dose
Bexagliflozin tablets, 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03259789
NCT03259789Phase 3Completed
CompareCT.gov

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Bexagliflozin in Subjects With Type 2 Diabetes Mellitus Who Are Not Adequately Controlled by Metformin Alone

Theracos·interventional·Posted Aug 24, 2017·Updated Jul 7, 2021

In Brief

A Phase 3 clinical trial evaluating Bexagliflozin tablets, 20 mg and Bexagliflozin tablets, placebo for Type2 Diabetes Mellitus. Completed, enrolled 351 participants across 43 sites in 2 countries.

Detailed Summary

The purpose of this study is to investigate the effect of bexagliflozin compared to placebo as an add-on therapy to metformin in lowering hemoglobin A1c (HbA1c) levels in subjects with type 2 diabetes mellitus (T2DM).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType2 Diabetes Mellitus
CountriesJapan, United States
Collaborators--

Timeline

Phase 3CompletedFinished
201820192020202120222023202420252026
First PostedAug 24, 2017
Enrollment StartNov 28, 2017
Primary CompletionJan 23, 2019
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 8.9 years ago

Interventions

Bexagliflozin tablets, 20 mgdrug

Each subject will receive bexagliflozin, 20 mg once daily for the duration of the study.

Bexagliflozin tablets, placebodrug

Each subject will receive placebo (inactive tablet) once daily for the duration of the study.

Bexagliflozin tablets, 20 mgdrug

Each subject will receive bexagliflozin, 20 mg once daily for the duration of the study.